Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma

Reuters

11/10

Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma

Lytix Biopharma AS and its partner Verrica have announced new clinical data from the Phase II study of ruxotemitide in basal cell carcinoma $(BCC)$. Results from this study were presented at SITC 2025, demonstrating a 97% calculated objective response rate and a 51% complete histologic clearance rate. The study also showed that ruxotemitide was well-tolerated and induced strong increases in cytotoxic CD8⁺ and helper CD4⁺ T cells, as well as B-cell infiltration, with a reduction in T-regulatory cells in the tumor microenvironment. These findings support further evaluation of ruxotemitide in a pivotal Phase III program in BCC. Additionally, interim results from the NeoLIPA Phase II study in melanoma will be presented at the Nordic Melanoma Meeting in Tromsø on November 11, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20251029:BIT:1646:0) on November 10, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582984141"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582984141\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582984141?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582984141","market":"fut","top_or_hot":-1,"title":"Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lytix Biopharma AS and its partner Verrica have announced new clinical data from the Phase II study of ruxotemitide in basal cell carcinoma <a href=\"https://laohu8.com/S/BCC\">$(BCC)$</a>. Results from this study were presented at SITC 2025, demonstrating a 97% calculated objective response rate and a 51% complete histologic clearance rate. The study also showed that ruxotemitide was well-tolerated and induced strong increases in cytotoxic CD8⁺ and helper CD4⁺ T cells, as well as B-cell infiltration, with a reduction in T-regulatory cells in the tumor microenvironment. These findings support further evaluation of ruxotemitide in a pivotal Phase III program in BCC. Additionally, interim results from the NeoLIPA Phase II study in melanoma will be presented at the Nordic Melanoma Meeting in Tromsø on November 11, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20251029:BIT:1646:0) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-10 14:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lytix Biopharma AS and its partner Verrica have announced new clinical data from the Phase II study of ruxotemitide in basal cell carcinoma <a href=\"https://laohu8.com/S/BCC\">$(BCC)$</a>. Results from this study were presented at SITC 2025, demonstrating a 97% calculated objective response rate and a 51% complete histologic clearance rate. The study also showed that ruxotemitide was well-tolerated and induced strong increases in cytotoxic CD8⁺ and helper CD4⁺ T cells, as well as B-cell infiltration, with a reduction in T-regulatory cells in the tumor microenvironment. These findings support further evaluation of ruxotemitide in a pivotal Phase III program in BCC. Additionally, interim results from the NeoLIPA Phase II study in melanoma will be presented at the Nordic Melanoma Meeting in Tromsø on November 11, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20251029:BIT:1646:0) on November 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VRCA","symbol_name":"Verrica Pharmaceuticals Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLbR0290:1","article_id":"2582984141","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582984141","pubTimestamp":1762754446,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lytix Biopharma AS and its partner Verrica have announced new clinical data from the Phase II study of ruxotemitide in basal cell carcinoma . Results from this study were presented at SITC 2025, demonstrating a 97% calculated objective response rate and a 51% complete histologic clearance rate. The study also showed that ruxotemitide was well-tolerated and induced strong increases in cytotoxic CD8 and helper CD4 T cells, as well as B-cell infiltration, with a reduction in T-regulatory cells in the tumor microenvironment. These findings support further evaluation of ruxotemitide in a pivotal Phase III program in BCC. Additionally, interim results from the NeoLIPA Phase II study in melanoma will be presented at the Nordic Melanoma Meeting in Troms on November 11, 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VRCA":"Verrica Pharmaceuticals Inc.","BK4007":"制药"},"translate_title":"Lytix Biopharma报告Ruxotemitide治疗基底细胞癌的强劲II期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRCA":0.9},"content_text":"Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma\n    \n\n        Lytix Biopharma AS and its partner Verrica have announced new clinical data from the Phase II study of ruxotemitide in basal cell carcinoma $(BCC)$. Results from this study were presented at SITC 2025, demonstrating a 97% calculated objective response rate and a 51% complete histologic clearance rate. The study also showed that ruxotemitide was well-tolerated and induced strong increases in cytotoxic CD8⁺ and helper CD4⁺ T cells, as well as B-cell infiltration, with a reduction in T-regulatory cells in the tumor microenvironment. These findings support further evaluation of ruxotemitide in a pivotal Phase III program in BCC. Additionally, interim results from the NeoLIPA Phase II study in melanoma will be presented at the Nordic Melanoma Meeting in Tromsø on November 11, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma AS published the original content used to generate this news brief via Cision (Ref. ID: 20251029:BIT:1646:0) on November 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}